S100A9 tetramers, which are ligands of CD85j, increase the ability of MVA HIV- primed NK cells to control HIV infection

1Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Natural killer (NK) cells are the major antiviral effector population of the innate immune system. We previously found that S100A9 is a novel ligand of the receptor CD85j and that S100A9 tetramers enhance the anti-HIV activity of NK cells. Also, we found that dendritic cells (DCs) infected by the HIV vaccine candidate, MVA HIV , prime NK cells to specifically control HIV infection in autologous CD4 + T cells. In this study, we analyzed whether stimulation of NK cells by S100A9 tetramers prior to the priming by MVA HIV- infected DCs modulates the subsequent anti-HIV activity of NK cells. We found that S100A9 tetramers activate NK cells and that DCs enhance the anti-HIV activity of NK cells. Interestingly, we observed that stimulation of NK cells by S100A9 tetramers, prior to the priming, significantly increased the subsequent anti-HIV activity of NK cells and that the enhanced anti-HIV activity was observed following different conditions of priming, including the MVA HIV- priming. As S100A9 tetramers alone directly increase the anti-HIV activity of NK cells and as this increased anti-HIV activity is also observed following the interaction of NK cells with MVA HIV- infected DCs, we propose S100A9 tetramers as potential adjuvants to stimulate the anti-HIV activity of NK cells.

Cite

CITATION STYLE

APA

Moreno-Nieves, U. Y., Didier, C., Lévy, Y., Barré-Sinoussi, F., & Scott-Algara, D. (2015). S100A9 tetramers, which are ligands of CD85j, increase the ability of MVA HIV- primed NK cells to control HIV infection. Frontiers in Immunology, 6(SEP). https://doi.org/10.3389/fimmu.2015.00478

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free